Mitragynine Stats & Data

Kratom’s main alkaloids are mitragynine and, at much lower natural abundance, 7‑hydroxymitragynine (7‑OH). Oral mitragynine is hepatically oxidized (primarily via CYP3A isoforms) to 7‑OH, which mediates much of its MOR‑agonist analgesia; CYP3A inhibition can reduce both analgesia and mitragynine‑linked respiratory effects in animals, indicating route- and enzyme‑dependent effects. Treat kratom like an opioid for safety: combining with alcohol, benzodiazepines, other opioids, or GHB/GBL substantially increases overdose risks including respiratory compromise and aspiration, even if mitragynine shows biased agonism relative to classical opioids. Leaf potency is highly variable (mitragynine commonly 12–21 mg/g; some resins 35.6–62.6 mg/g), so dose titration is essential; avoid rapid re‑dosing because nausea and delayed peaks are common. Be wary of ‘enhanced’ or ‘fortified’ products: ‘Krypton’ products in Europe were adulterated with O‑desmethyltramadol and associated with deaths. Rare but documented kratom‑associated cholestatic liver injury exists; discontinue and seek care if pruritus, dark urine, jaundice, or severe abdominal pain occur. Pregnancy and lactation: neonatal opioid withdrawal has been reported with maternal kratom use; breastfeeding is discouraged due to unknown infant exposure to multiple CNS‑active alkaloids. Because mitragynine can inhibit CYP2D6/3A in vitro, co‑medications metabolized by these pathways (e.g., many antidepressants, antipsychotics, beta‑blockers, opioids) may have altered levels; avoid intentional potentiation with strong CYP3A inhibitors (e.g., grapefruit, certain azoles/macrolides) and monitor for adverse effects. High‑dose, chronic use can cause constipation, sweating, dizziness, and tolerance; maintain hydration, fiber intake, and consider periodic ‘off‑days’ to reduce escalation. Do not drive or operate machinery while sedated.